| Literature DB >> 28790448 |
Fan Wang1,2, Zhi-An Huang3, Xing Chen4, Zexuan Zhu5, Zhenkun Wen3, Jiyun Zhao1, Gui-Ying Yan6.
Abstract
An increasing number of evidences indicate microbes are implicated in human physiological mechanisms, including complicated disease pathology. Some microbes have been demonstrated to be associated with diverse important human diseases or disorders. Through investigating these disease-related microbes, we can obtain a better understanding of human disease mechanisms for advancing medical scientific progress in terms of disease diagnosis, treatment, prevention, prognosis and drug discovery. Based on the known microbe-disease association network, we developed a semi-supervised computational model of Laplacian Regularized Least Squares for Human Microbe-Disease Association (LRLSHMDA) by introducing Gaussian interaction profile kernel similarity calculation and Laplacian regularized least squares classifier. LRLSHMDA reached the reliable AUCs of 0.8909 and 0.7657 based on the global and local leave-one-out cross validations, respectively. In the framework of 5-fold cross validation, average AUC value of 0.8794 +/-0.0029 further demonstrated its promising prediction ability. In case studies, 9, 9 and 8 of top-10 predicted microbes have been manually certified to be associated with asthma, colorectal carcinoma and chronic obstructive pulmonary disease by published literature evidence. Our proposed model achieves better prediction performance relative to the previous model. We expect that LRLSHMDA could offer insights into identifying more promising human microbe-disease associations in the future.Entities:
Mesh:
Year: 2017 PMID: 28790448 PMCID: PMC5548838 DOI: 10.1038/s41598-017-08127-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flowchart of LRLSHMDA. Based on the known microbe-disease association network, we utilized Gaussian interaction profile kernel similarity and LapRLS classification to infer the potential microbe-disease associations.
Figure 2Prediction performance comparison between LRLSHMDA and KATZHMDA in the frameworks of both global and local LOOCV.
In the case study of asthma, 9 out of top-10 predicted microbes have been supported by literature evidences.
| Rank | Microbe | Evidence |
|---|---|---|
| 1 | Pseudomonas | PMID:9294308 |
| 2 | Clostridium difficile | PMID:21872915 |
| 3 | Lactobacillus | PMID:20592920 |
| 4 | Burkholderia | unconfirmed |
| 5 | Actinobacteria | PMID:23265859 |
| 6 | Firmicutes | PMID:23265859 |
| 7 | Clostridium coccoides | PMID:21477358 |
| 8 | Clostridia | PMID:21477358 |
| 9 | Staphylococcus aureus | PMID:17950502 |
| 10 | Bifidobacterium | PMID:24735374 |
In the case study of colorectal carcinoma, 9 out of top-10 predicted microbes have been supported by literature evidences.
| Rank | Microbe | Evidence |
|---|---|---|
| 1 | Proteobacteria | unconfirmed |
| 2 | Helicobacter pylori | PMID:11774957 |
| 3 | Clostridium difficile | PMID:19807912 |
| 4 | Clostridium coccoides | PMID:19807912 |
| 5 | Staphylococcus aureus | PMID:7074582 |
| 6 | Bifidobacterium | PMID:9111222 |
| 7 | Haemophilus | PMID:22761885 |
| 8 | Actinobacteria | PMID:24316595 |
| 9 | Lactobacillus | PMID:15828052 |
| 10 | Veillonella | PMID:22761885 |
In the case study of COPD, 8 out of top-10 predicted microbes have been supported by literature evidences.
| Rank | Microbe | Evidence |
|---|---|---|
| 1 | Helicobacter pylori | PMID:15733502 |
| 2 | Clostridium difficile | PMID:15655746 |
| 3 | Clostridium coccoides | unconfirmed |
| 4 | Actinobacteria | PMID:26852737 |
| 5 | Staphylococcus | PMID:15338798 |
| 6 | Firmicutes | PMID:24591822 |
| 7 | Clostridia | PMID:26852737 |
| 8 | Comamonadaceae | PMID:20141328 |
| 9 | Oxalobacteraceae | unconfirmed |
| 10 | Sphingomonadaceae | PMID:26852737 |
Performance comparison between LRLSHMDA and KATZHMDA in the case studies of the confirmation of the top-10 prediction list for three human complex diseases.
| Model | Asthma | Colorectal carcinoma | COPD |
|---|---|---|---|
| LRLSHMDA | 9 | 9 | 8 |
| KATZHMDA | 4 | 5 | 5 |